Relay Therapeutics, Inc. RLAY
19.72 USD -0.22 (-1.10%)
At closeNov 11, 2026, 6:27 PM EST
19.58 -0.14 -0.73%
After hours · Nov 11, 6:27 PM ET
19.69 Day range 20.21
6.04 52-week range 21.27
- YTD
- +133.10%
- 1 year
- +213.51%
News
seekingalpha.com Relay Therapeutics, Inc. (RLAY) Presents at 3rd Annual Guggenheim Healthcare Innovation Conference Transcript Relay Therapeutics, Inc. ( RLAY ) 3rd Annual Guggenheim Healthcare Innovation Conference November 10, 2026 4:30 PM EST Company Participants Sanjiv Patel - CEO, President & Director Peter Rahmer -…
benzinga.com Jones Trading Maintains Buy on Relay Therapeutics, Raises Price Target to $31 Jones Trading analyst Boris Peaker maintains Relay Therapeutics (NASDAQ:RLAY) with a Buy and raises the price target from $20 to $31.
benzinga.com Relay Therapeutics Q3 EPS $(0.37) Beats $(0.40) Estimate Relay Therapeutics (NASDAQ:RLAY) reported quarterly losses of $(0.37) per share which beat the analyst consensus estimate of $(0.40) by 7.5 percent. This is a 13.95 percent increase over losses of…
globenewswire.com Relay Therapeutics Reports Third Quarter 2026 Financial Results and Corporate Updates Phase 3 ReDiscover-2 trial in 2L breast cancer expected to complete enrollment in mid-2027 Updated data from ongoing Phase 1/2 ReInspire trial of zovegalisib in vascular anomalies to be featured in…
benzinga.com HC Wainwright & Co. Maintains Buy on Relay Therapeutics, Raises Price Target to $29 HC Wainwright & Co. analyst Robert Burns maintains Relay Therapeutics (NASDAQ:RLAY) with a Buy and raises the price target from $28 to $29.- benzinga.com JP Morgan Maintains Overweight on Relay Therapeutics, Raises Price Target to $31 JP Morgan analyst Priyanka Grover maintains Relay Therapeutics (NASDAQ:RLAY) with a Overweight and raises the price target from $28 to $31.
benzinga.com Citizens Maintains Market Outperform on Relay Therapeutics, Raises Price Target to $26 Citizens analyst Silvan Turkcan maintains Relay Therapeutics (NASDAQ:RLAY) with a Market Outperform and raises the price target from $21 to $26.- benzinga.com Barclays Maintains Overweight on Relay Therapeutics, Raises Price Target to $30 Barclays analyst Etzer Darout maintains Relay Therapeutics (NASDAQ:RLAY) with a Overweight and raises the price target from $27 to $30.
- benzinga.com Relay Therapeutics Q2 EPS $(0.41) Misses $(0.39) Estimate, Sales $350.000K Miss $872.727K Estimate Relay Therapeutics (NASDAQ:RLAY) reported quarterly losses of $(0.41) per share which missed the analyst consensus estimate of $(0.39) by 5.13 percent. This is unchanged from the same period last…
benzinga.com Goldman Sachs Maintains Buy on Relay Therapeutics, Raises Price Target to $31 Goldman Sachs analyst Salveen Richter maintains Relay Therapeutics (NASDAQ:RLAY) with a Buy and raises the price target from $22 to $31.
benzinga.com Canaccord Genuity Initiates Coverage On Relay Therapeutics with Buy Rating, Announces Price Target of $29 Canaccord Genuity analyst John Newman initiates coverage on Relay Therapeutics (NASDAQ:RLAY) with a Buy rating and announces Price Target of $29.- benzinga.com JP Morgan Initiates Coverage On Relay Therapeutics with Overweight Rating, Announces Price Target of $28 JP Morgan analyst Priyanka Grover initiates coverage on Relay Therapeutics (NASDAQ:RLAY) with a Overweight rating and announces Price Target of $28.
- benzinga.com Guggenheim Maintains Buy on Relay Therapeutics, Raises Price Target to $26 Guggenheim analyst Brad Canino maintains Relay Therapeutics (NASDAQ:RLAY) with a Buy and raises the price target from $22 to $26.
- benzinga.com HC Wainwright & Co. Maintains Buy on Relay Therapeutics, Raises Price Target to $28 HC Wainwright & Co. analyst Robert Burns maintains Relay Therapeutics (NASDAQ:RLAY) with a Buy and raises the price target from $25 to $28.
benzinga.com Advance Auto Parts Posts Upbeat Q1 Earnings, Joins IBM, Ralph Lauren And Other Big Stocks Moving Higher On Thursday U.S. stocks were lower on Thursday, with Nasdaq falling over 200 points. Advance Auto Parts Inc (NYSE: AAP) jumped 16.4% after reporting better-than-expected Q1 results.- benzinga.com Barclays Maintains Overweight on Relay Therapeutics, Raises Price Target to $27 Barclays analyst Etzer Darout maintains Relay Therapeutics (NASDAQ:RLAY) with a Overweight and raises the price target from $21 to $27.
- benzinga.com Citizens Maintains Market Outperform on Relay Therapeutics, Raises Price Target to $21 Citizens analyst Silvan Turkcan maintains Relay Therapeutics (NASDAQ:RLAY) with a Market Outperform and raises the price target from $19 to $21.
benzinga.com Lowe's, ZTO Express, Viavi Solutions And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session US stock futures higher, Lowe's shares fall after reporting earnings. Other stocks declining in pre-market trading. Photo via Shutterstock- benzinga.com Relay Therapeutics Launches $175M Public Stock Offering Relay Therapeutics, Inc. (NASDAQ:RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease,…
- benzinga.com Raymond James Maintains Strong Buy on Relay Therapeutics, Raises Price Target to $26 Raymond James analyst Dane Leone maintains Relay Therapeutics (NASDAQ:RLAY) with a Strong Buy and raises the price target from $23 to $26.
benzinga.com Relay Therapeutics Reports Early Success For Investigational Drug In Rare Vascular Disorders Relay Therapeutics reported early Phase 2 data showing lesion reduction and symptom improvement with zovegalisib.
benzinga.com Relya Therapeutics Announces Initial Clinical Data From The Phase 2 ReInspire Trial Of Zovegalisib In Vascular Anomalies Promising initial efficacy data with 60% volumetric response rate across doses and 29%* at the lowest tested dose of 100mg twice daily (BID) with all patients ongoingInterim investigator- and…- benzinga.com Relay Therapeutics Q1 EPS $(0.41) Misses $(0.37) Estimate, Sales $3.000M Beat $2.560M Estimate Relay Therapeutics (NASDAQ:RLAY) reported quarterly losses of $(0.41) per share which missed the analyst consensus estimate of $(0.37) by 10.81 percent. This is a 10.87 percent increase over losses…
benzinga.com Earnings Scheduled For May 5, 2026 
benzinga.com Starbucks To Rally More Than 18%? Here Are 10 Top Analyst Forecasts For Wednesday Analysts change outlook & ratings for QGEN, AWI, CR, ATEN, PLUG, SBUX, CECO, CNC. Price targets raised for QGEN, AWI, CR, ATEN, PLUG, SBUX, CECO.
benzinga.com HC Wainwright & Co. Maintains Buy on Relay Therapeutics, Raises Price Target to $25 HC Wainwright & Co. analyst Robert Burns maintains Relay Therapeutics (NASDAQ:RLAY) with a Buy and raises the price target from $19 to $25.
benzinga.com Goldman Sachs Maintains Buy on Relay Therapeutics, Raises Price Target to $22 Goldman Sachs analyst Salveen Richter maintains Relay Therapeutics (NASDAQ:RLAY) with a Buy and raises the price target from $13 to $22.- benzinga.com Citizens Maintains Market Outperform on Relay Therapeutics, Raises Price Target to $19 Citizens analyst Silvan Turkcan maintains Relay Therapeutics (NASDAQ:RLAY) with a Market Outperform and raises the price target from $17 to $19.
benzinga.com Wells Fargo Maintains Overweight on Relay Therapeutics, Raises Price Target to $21 Wells Fargo analyst Eva Fortea Verdejo maintains Relay Therapeutics (NASDAQ:RLAY) with a Overweight and raises the price target from $17 to $21.- benzinga.com Oppenheimer Maintains Outperform on Relay Therapeutics, Raises Price Target to $18 Oppenheimer analyst Matthew Biegler maintains Relay Therapeutics (NASDAQ:RLAY) with a Outperform and raises the price target from $14 to $18.
- benzinga.com Relay Therapeutics Plans To Move Zovegalisib + Atirmociclib, Pfizer's Investigational, CDK4 Inhibitor, Into Phase 3 Development For Frontline Patients With PI3Kα-Mutated, HR+/HER2- Metastatic Breast Cancer Zovegalisib + atirmociclib + AI selected as triplet regimen for frontline developmentCompelling efficacy and tolerability data for zovegalisib triplet in median 3L patients44% ORR in heavily…
- benzinga.com Jones Trading Initiates Coverage On Relay Therapeutics with Hold Rating, Announces Price Target of $18 Jones Trading analyst Boris Peaker initiates coverage on Relay Therapeutics (NASDAQ:RLAY) with a Hold rating and announces Price Target of $18.
- benzinga.com Barclays Maintains Overweight on Relay Therapeutics, Raises Price Target to $21 Barclays analyst Etzer Darout maintains Relay Therapeutics (NASDAQ:RLAY) with a Overweight and raises the price target from $17 to $21.
- benzinga.com Relay Therapeutics To Present Initial Clinical Results, Preclinical Data For Zovegalisib In Vascular Anomalies At International Society For The Study Of Vascular Anomalies World Congress 2026 Relay Therapeutics, Inc. (NASDAQ:RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease,…
benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session - benzinga.com HC Wainwright & Co. Maintains Buy on Relay Therapeutics, Raises Price Target to $19 HC Wainwright & Co. analyst Robert Burns maintains Relay Therapeutics (NASDAQ:RLAY) with a Buy and raises the price target from $14 to $19.
- benzinga.com Citizens Maintains Market Outperform on Relay Therapeutics, Raises Price Target to $17 Citizens analyst Silvan Turkcan maintains Relay Therapeutics (NASDAQ:RLAY) with a Market Outperform and raises the price target from $15 to $17.
- benzinga.com Wells Fargo Maintains Overweight on Relay Therapeutics, Raises Price Target to $17 Wells Fargo analyst Eva Fortea Verdejo maintains Relay Therapeutics (NASDAQ:RLAY) with a Overweight and raises the price target from $15 to $17.
benzinga.com Relay Therapeutics' Cancer Drug Hits 11.1-Month Progression Free Survival - What Does This Means For Pretreated Breast Cancer Patients? Relay Therapeutics shares rise after Phase 3 data show zovegalisib achieved 11.1-month PFS in metastatic breast cancer patients.- benzinga.com Guggenheim Maintains Buy on Relay Therapeutics, Raises Price Target to $22 Guggenheim analyst Brad Canino maintains Relay Therapeutics (NASDAQ:RLAY) with a Buy and raises the price target from $15 to $22.
- benzinga.com Wells Fargo Maintains Overweight on Relay Therapeutics, Raises Price Target to $15 Wells Fargo analyst Eva Fortea Verdejo maintains Relay Therapeutics (NASDAQ:RLAY) with a Overweight and raises the price target from $13 to $15.
- benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session
benzinga.com Relay Therapeutics Q4 Earnings Assessment - benzinga.com Earnings Scheduled For February 26, 2026
benzinga.com Relay Therapeutics Earnings Preview - benzinga.com Oppenheimer Upgrades Relay Therapeutics to Outperform, Announces $14 Price Target Oppenheimer analyst Matthew Biegler upgrades Relay Therapeutics (NASDAQ:RLAY) from Perform to Outperform and announces $14 price target.
benzinga.com Relay Therapeutics Reports 'Robust Activity' For Precision Breast Cancer Drug Relay Therapeutics shared interim data for zovegalisib at SABCS 2025, showing consistent efficacy in breast cancer patients.- benzinga.com Wells Fargo Upgrades Relay Therapeutics to Overweight, Raises Price Target to $13 Wells Fargo analyst Eva Fortea Verdejo upgrades Relay Therapeutics (NASDAQ:RLAY) from Equal-Weight to Overweight and raises the price target from $6 to $13.
- benzinga.com Relay Therapeutics Presents Subset Analysis Of Interim Phase 3 Data For Zovegalisib At SABCS 2025 Efficacy data remain consistent with previous disclosures, showing 10.3-month median PFS in all patients and 11.4-month median PFS in 2L patientsSubset analyses show broad activity in patients with…
benzinga.com Alibaba, Oscar Health, Ondas Holdings, Lumentum, Tesla And Other Big Stocks Moving Higher On Monday